Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Share-based Compensation: 2014-2025

Historic Share-based Compensation for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to $8.9 million.

  • ImmunityBio's Share-based Compensation rose 18.55% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year decrease of 2.80%. This contributed to the annual value of $34.4 million for FY2024, which is 29.96% down from last year.
  • Per ImmunityBio's latest filing, its Share-based Compensation stood at $8.9 million for Q3 2025, which was down 7.98% from $9.6 million recorded in Q2 2025.
  • ImmunityBio's 5-year Share-based Compensation high stood at $17.9 million for Q2 2021, and its period low was $7.5 million during Q3 2024.
  • Its 3-year average for Share-based Compensation is $10.2 million, with a median of $9.6 million in 2024.
  • In the last 5 years, ImmunityBio's Share-based Compensation surged by 5,447.52% in 2021 and then tumbled by 48.17% in 2024.
  • Over the past 5 years, ImmunityBio's Share-based Compensation (Quarterly) stood at $10.2 million in 2021, then declined by 8.15% to $9.3 million in 2022, then surged by 36.62% to $12.8 million in 2023, then dropped by 29.25% to $9.0 million in 2024, then climbed by 18.55% to $8.9 million in 2025.
  • Its last three reported values are $8.9 million in Q3 2025, $9.6 million for Q2 2025, and $9.5 million during Q1 2025.